Posted by Tomatheus on December 28, 2005, at 0:44:10
In reply to Re: What to do if Nardil and Parnate were discontinued » Tomatheus, posted by ed_uk on December 27, 2005, at 12:12:12
> So what do you think of ladostigil?
It definitely sounds like ladostigil has a lot of potential, particularly because of its "brain selectivity." The drug companies are obviously not interested in developing any more MAOIs that carry a significant risk of potentiating a tyramine-induced hypertensive crisis, so it's possible that ladostigil might end up becoming a highly desirable medication. I do think that its efficacy will need to be established first, though. In my opinion, if ladostigil is capable of inhibiting both MAO-A and MAO-B in a manner that is consistent over time, there is a good chance that it will turn out to be one of the more effective MAOIs on the market. Of course, there are other factors that could influence the drug's efficacy. But no matter what factors contribute to ladostigil's efficacy (or lack thereof, if that turns out to be the case), it's obviously important from our perspective as patients that the drug is reasonably effective. I also think that ladostigil's potential as an antidepressant might be hampered by the fact that it functions as both an MAOI and a cholinesterase inhibitor, depending on the potency of the drug's cholinesterase inhibition. Personally, I wouldn't have a problem with combining ladostigil with an anticholinergic, as long as the ladostigil provided me with a clinically significant remission. Other patients, however, might find the addition of an anticholinergic to be too much of a hassle, especially if their response to ladostigil is less than robust.
Tomatheus
poster:Tomatheus
thread:591969
URL: http://www.dr-bob.org/babble/20051221/msgs/592664.html